Cargando…

Durable response to olaparib combined low-dose cisplatin in advanced hepatocellular carcinoma with FANCA mutation: A case report

To date, there is no actionable gene has been discovered in hepatocellular carcinoma (HCC). Tumor cells with DNA damage response and repair (DDR) gene loss-of-function mutation is sensitivity to poly-ADP-ribose polymerase (PARP) inhibitors and platinum chemotherapy in ovarian, prostate and pancreati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lai, Yi-Hsuan, Tung, Kai-Che, Chen, San-Chi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524966/ https://www.ncbi.nlm.nih.gov/pubmed/36181052 http://dx.doi.org/10.1097/MD.0000000000030719

Ejemplares similares

Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer
por: Yarchoan, Mark, et al.
Publicado: (2017)

FANCA Gene Mutations in North African Fanconi Anemia Patients
por: Ben Haj Ali, Abir, et al.
Publicado: (2021)

Combination treatment with cisplatin, paclitaxel and olaparib has synergistic and dose reduction potential in ovarian cancer cells
por: Gao, Jianwen, et al.
Publicado: (2021)

Durable response to olaparib in pancreatic duct adenocarcinoma with deleterious ARID1A mutation
por: Zhao, Xue-Song, et al.
Publicado: (2019)

Remarkable Response to Olaparib in a Patient with Combined Hepatocellular-Cholangiocarcinoma Harboring a Biallelic BRCA2 Mutation
por: Su, Yu-Li, et al.
Publicado: (2021)

Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2‐Year Durable Response
por: Valiakhmetova, Andge, et al.
Publicado: (2019)

A Multiple Primary Malignancy Patient With FANCA Gene Mutation: A Case Report and Literature Review
por: Xia, Qing, et al.
Publicado: (2020)

Hypomorphic FANCA mutations correlate with mild mitochondrial and clinical phenotype in Fanconi anemia
por: Bottega, Roberta, et al.
Publicado: (2018)

Structural basis of the fanconi anemia-associated mutations within the FANCA and FANCG complex
por: Jeong, Eunyoung, et al.
Publicado: (2020)

Coregulation of FANCA and BRCA1 in human cells
por: Haitjema, Anneke, et al.
Publicado: (2014)

Two cases of CRPC with BRCA mutation treated by olaparib after favorable response to cisplatin
por: Miyazawa, Yoshiyuki, et al.
Publicado: (2022)

FANCA Gene Mutations with 8 Novel Molecular Changes in Indian Fanconi Anemia Patients
por: Solanki, Avani, et al.
Publicado: (2016)

Investigation of FANCA gene in Fanconi anaemia patients in Iran
por: Saffar Moghadam, Ali Akbar, et al.
Publicado: (2016)

Rare variants in FANCA induce premature ovarian insufficiency
por: Yang, Xi, et al.
Publicado: (2019)

Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations)
por: Mahdi, Haider, et al.
Publicado: (2021)

FANCA deficiency promotes leukaemic progression by allowing the emergence of cells carrying oncogenic driver mutations
por: Pawlikowska, Patrycja, et al.
Publicado: (2023)

Olaparib: Transcending mutational barriers
por: Chandna, Abhishek
Publicado: (2019)

Olaparib and somatic BRCA mutations
por: George, Angela, et al.
Publicado: (2017)

A Phase I dose‐escalation study of two cycles carboplatin‐olaparib followed by olaparib monotherapy in patients with advanced cancer
por: Geenen, Jill J. J., et al.
Publicado: (2021)

FANCA Polymorphism Is Associated with the Rate of Proliferation in Uterine Leiomyoma in Korea
por: Ha, Eunyoung, et al.
Publicado: (2020)

Fanca deficiency is associated with alterations in osteoclastogenesis that are rescued by TNFα
por: Oppezzo, Alessia, et al.
Publicado: (2023)

Editorial Comment on “Two cases of CRPC with BRCA mutation treated by olaparib after favorable response to cisplatin”
por: Hatano, Koji
Publicado: (2022)

FANCA D1359Y mutation in a patient with gastric polyposis and cancer susceptibility: A case report and review of literature
por: Huang, Jeffrey Peng, et al.
Publicado: (2018)

Identification of Three Novel Mutations in the FANCA, FANCC, and ITGA2B Genes by Whole Exome Sequencing
por: Negahdari, Samira, et al.
Publicado: (2020)

Novel FANCA mutation in the first fully-diagnosed patient with Fanconi anemia in Polish population – case report
por: Repczynska, Anna, et al.
Publicado: (2020)

Altered Mitochondrial Dynamic in Lymphoblasts and Fibroblasts Mutated for FANCA-A Gene: The Central Role of DRP1
por: Bertola, Nadia, et al.
Publicado: (2023)

Synergistic effects of olaparib combined with ERCC1 on the sensitivity of cisplatin in non-small cell lung cancer
por: Xie, Kejie, et al.
Publicado: (2021)

Treatment of FANCA Cells with Resveratrol and N-Acetylcysteine: A Comparative Study
por: Columbaro, Marta, et al.
Publicado: (2014)

Mutated FANCA Gene Role in the Modulation of Energy Metabolism and Mitochondrial Dynamics in Head and Neck Squamous Cell Carcinoma
por: Bertola, Nadia, et al.
Publicado: (2022)

The combination of olaparib and camptothecin for effective radiosensitization
por: Miura, Katsutoshi, et al.
Publicado: (2012)

MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib
por: Whicker, Margaret E., et al.
Publicado: (2016)

Retrospective efficacy analysis of olaparib combined with bevacizumab in the treatment of advanced colorectal cancer
por: Jiang, Yi-Ling, et al.
Publicado: (2023)

Does FANCA Assist CENP-E in Architectural Organization of Chromosomes at Spindle Equator?
por: El-Arabey, Amr Ahmed, et al.
Publicado: (2018)

A germline FANCA alteration that is associated with increased sensitivity to DNA damaging agents
por: Wilkes, David C., et al.
Publicado: (2017)

Clinical Benefit With PARP Inhibitor for Pathogenic Germline FANCA-Mutated Relapsed Epithelial Ovarian Cancer: A Case Report
por: Qian, Bing, et al.
Publicado: (2022)

Durable Near-Complete Response to Olaparib Plus Temozolomide and Radiation in a Patient With ATM-Mutated Glioblastoma and MSH6-Deficient Lynch Syndrome
por: File, Danielle M., et al.
Publicado: (2020)

Olaparib Treatment in a Patient with Advanced Gallbladder Cancer Harboring BRCA1 Mutation
por: Li, Xiaofen, et al.
Publicado: (2021)

Profile of olaparib in the treatment of advanced ovarian cancer
por: Chase, Dana M, et al.
Publicado: (2016)

Inhibiting the MCM8‐9 complex selectively sensitizes cancer cells to cisplatin and olaparib
por: Morii, Issay, et al.
Publicado: (2019)

Novel Founder Mutation in FANCA Gene (c.3446_3449dupCCCT) Among Romani Patients from the Balkan Region
por: Dimishkovska, Marija, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_1vi5n7rjoupm275obkcf57ca30